



CHF Solutions to Exhibit at The International Society for Heart and Lung Transplantation 2019 Annual Meeting and Scientific Sessions

March 28, 2019

EDEN PRAIRIE, Minn., March 28, 2019 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), today announced it will be exhibiting at the 2019 Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) on April 3-6, 2019 at the Lowes Meeting Complex in Orlando, Fla. The company can be found on the exhibition floor at booth #408.

"We continue to expand our reach within the cardiovascular community in order to demonstrate the value of ultrafiltration therapy in post-operative cardiac surgery. We recently announced the additional focus of using the Aquadex Flex Flow system post-surgery, and we believe that the ISHLT is an excellent opportunity to increase awareness," said John Erb, chairman and CEO of CHF Solutions.

About the ISHLT

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy. The purposes of the Society are: promoting the association of persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease and related sciences; encouraging and stimulating basic and clinical research in heart and lung transplantation and end-stage heart and lung disease, and promoting new therapeutic strategies; holding scientific meetings featuring presentations and discussions relevant to heart and lung transplantation and the treatment of end-stage heart and lung disease; sponsoring a scientific journal for the publication of manuscripts related to these disciplines; maintaining an international registry for heart and lung transplantation; awarding research grants and establishing endowments for the study of heart and lung transplantation and end-stage heart and lung disease, when funds are available and without jeopardizing the financial well-being of the organization; and sponsoring and conducting educational activities and providing educational resources, which promote expert development and improve standards of care in advanced heart and lung disease, heart and lung transplantation, and relevant medical and device therapies.

About CHF Solutions

CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow® system for aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, the company's plans for the Society of Thoracic Surgeons Annual Meeting. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:

INVESTORS:

Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com

-or-

Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com

MEDIA

Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com

chf solutions

Source: CHF Solutions, Inc.